Related Experiment Videos

Renin-angiotensin system antagonism and lipid-lowering therapy in cardiovascular risk management

Jun R Chiong1, Alan B Miller

  • 1Health Science Center, University of Florida, Jacksonville, Florida 32209, USA. jun.chiong@jax.ufl.edu

Journal of the Renin-Angiotensin-Aldosterone System : JRAAS
|September 14, 2002
PubMed

Insights

Statins and renin-angiotensin system (RAS) blockers offer cardiovascular benefits beyond lowering lipids and blood pressure. These drugs share properties that improve endothelial function and inhibit cell proliferation, aiding atherosclerosis treatment.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology

Background:

  • Atherosclerosis development and progression involve the renin-angiotensin system (RAS) and dyslipidemia.
  • The RAS and statins are implicated in the pathogenesis of atherosclerosis.
  • Both RAS blockers and statins have demonstrated efficacy in managing coronary artery disease (CAD).

Purpose of the Study:

  • To review the shared properties of RAS blockers and statins.
  • To explore beneficial effects beyond their primary actions in cardiovascular disease.

Main Methods:

  • Review of current scientific literature and clinical trial data.
  • Analysis of pharmacological actions and clinical outcomes associated with RAS inhibitors and statins.

Main Results:

  • Statins and RAS blockers share pleiotropic effects.
  • These effects include restoration of endothelial function and inhibition of cellular proliferation.
  • Beneficial outcomes extend beyond lipid-lowering and antihypertensive effects.

Conclusions:

  • Statins and RAS blockers possess common beneficial properties.
  • These shared characteristics contribute to managing atherosclerosis and cardiovascular events.
  • Further research into these combined effects may offer novel therapeutic strategies.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...